Original Articles

Clinical Utility of the BioFire Meningitis/Encephalitis (ME) Panel in Diagnosing Central Nervous System Infections: A One-Year Prospective Study at GB Pant Hospital

Abstract

Background:    Central nervous system (CNS) infections are life-threatening medical emergencies requiring rapid and accurate diagnosis. This prospective study compared the BioFire Meningitis/Encephalitis (ME) Panel with conventional diagnostics in suspected cases.

Methods:   We conducted a single-center, prospective study at GB Pant Hospital from January to December 2024, enrolling 100 consecutive patients with clinical suspicion of meningitis or encephalitis. Cerebrospinal fluid (CSF) samples were simultaneously analysed using the BioFire ME Panel and conventional diagnostic methods (culture, Gram stain, cytology). Clinical data including demographics, risk factors, prior antimicrobial therapy, and outcomes were recorded.

Results:   The BioFire ME Panel detected pathogens in 7% (7/100) of cases, comprising Streptococcus pneumoniae (n=2), Haemophilus influenzae (n=1), Escherichia coli K1 (n=1), herpes simplex virus (n=2), and cytomegalovirus (n=1). In two culture-negative cases with prior antibiotic exposure, the panel successfully identified bacterial pathogens despite negative Gram stain results. The panel demonstrated excellent diagnostic performance (sensitivity 100%, specificity 98.9%, PPV 87.5%, NPV 100%) with a median time-to-result of 65 minutes versus 72 hours for conventional cultures. Implementation of the panel led to therapy modifications in 71.4% (5/7) of positive cases, including de-escalation of empiric therapy in 3 cases and targeted antiviral initiation in 2 cases.

Conclusion:   The BioFire ME Panel demonstrates superior diagnostic utility in CNS infection diagnosis, particularly in culture-negative cases with prior antimicrobial exposure. Its rapid turnaround time facilitates prompt clinical decision-making and appropriate antimicrobial stewardship, suggesting significant value as a complementary diagnostic tool in the management of suspected meningitis and encephalitis.

1. Van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22:S37-62.
2. Ali M, Chang BA, Johnson KW, et al. Incidence and aetiology of bacterial meningitis among children aged 1–59 months in South Asia: Systematic review and meta-analysis. Vaccine 2018; 36(39):5846-57.
3. World Health Organization. WHO guidelines on meningitis diagnosis, treatment and care. Web annex B: qualitative and economic evidence reports. Geneva: World Health Organization; 2025. https://www.who.int/publications/i/item/ 9789240108042
4. Myint T, Soria J, Gao Y, et al. Comparison of positive BioFire FilmArray meningitis/encephalitis (ME) panels, CSF cultures, CSF parameters, clinical presentation and in-patient mortality among patients with bacterial and fungal meningitis. Microbiol Spectr 2025; 13(2):e0001424.
5. Rafiei N, Subedi S, Harris PN, et al. Clinical and cost implications of Biofire FilmArray® meningitis/encephalitis panel testing: A systematic review. Diagn Microbiol Infect Dis 2025; 112(3):116823.
6. Chandran S, Arjun R, Sasidharan A, et al. Clinical performance of FilmArray meningitis/encephalitis multiplex polymerase chain reaction panel in central nervous system infections. Indian J Crit Care Med 2022; 26(1):67-70.
7. Rogers T, Sok K, Erickson T, et al. Impact of antibiotic therapy in the microbiological yield of healthcare–associated ventriculitis and meningitis. Open Forum Infect Dis 2019; 6(3):ofz050.
8. Nigrovic LE, Malley R, Macias CG, et al. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics 2008; 122(4):726-30.
9. Rasti R, Kumbakumba E, Nanjebe D, et al. Clinical utility of the FilmArray® meningitis/encephalitis panel in children with suspected central nervous system infection in a low-resource setting – A prospective study in Southwestern Uganda. BMC Infect Dis 2025; 25(1):396.
10. Ekambaram M, Nabower AM, Ampofo K, et al. Evaluation of discordant results between filmarray meningitis/encephalitis panel and conventional testing in pediatric patients: A multi-site retrospective cohort study. Open Forum Infect Dis 2020; 7(1):S154-5.
11. Waldrop G, Zucker J, Boubour A, et al. Clinical significance of positive results of the BioFire cerebrospinal fluid FilmArray Meningitis/Encephalitis panel at a tertiary medical center in the United States. Arch Pathol Lab Med 2022; 146(2):194-200.
12. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter evaluation of BioFire FilmArray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016; 54(9):2251-61.
13. Sunnerhagen T, Widén J, Handhal S, et al. A retrospective observational study of 1000 consecutive patients tested with the FilmArray® Meningitis/Encephalitis panel: Clinical diagnosis at discharge and microbiological findings. Sci Rep 2024; 14(1):4015.
14. Miyazaki Y, Tominaga K, Adachi T. Diagnosis of Listeria monocytogenes meningitis using the FilmArray Meningitis/Encephalitis panel in a patient with prior antibiotic exposure: A case report. Cureus 2025; 17(7):e87687.
15. Hovmand N, Lundbo LF, Kronborg G, et al. Factors associated with treatment delay and outcome in community acquired bacterial meningitis. IJID Regions 2023; 7:176-81.
IssueVol 13 No 4 (2025) QRcode
SectionOriginal Articles
Keywords
BioFire ME Panel Central nervous system infections Encephalitis Meningitis Multiplex PCR.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Goenka S, Wanswett W, Sharma A, Loomba P, Jain M, Tyagi S. Clinical Utility of the BioFire Meningitis/Encephalitis (ME) Panel in Diagnosing Central Nervous System Infections: A One-Year Prospective Study at GB Pant Hospital. J Med Bacteriol. 2025;13(4):45-55.